JPMorgan analyst Jessica Fye raised the firm’s price target on Halozyme (HALO) to $65 from $63 and keeps a Neutral rating on the shares. The firm updated the company’s model ahead of the Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Buy Rating for Halozyme: Strong Growth Prospects Backed by Successful MajesTEC-3 Trial and Robust Financial Valuation
- Halozyme price target lowered to $79 from $80 at Morgan Stanley
- Halozyme’s Strong Royalty Revenue and Strategic Initiatives Justify Buy Rating Despite Potential Risks
- Halozyme’s Strong Financial Outlook and Strategic Investment Potential Amidst Policy Stability
- Halozyme upgraded at Leerink on lower-than-feared Part B exposure